Contributions
Abstract: P1017
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - 19 Neurodegeneration
Background: Brain volume loss is part of lifetime brain changes and it starts to accelerate at the age of 60 in healthy individuals (HI). Lateral ventricular volume (LVV) enlargement is accelerated in multiple sclerosis (MS) patients from the disease onset. Whether there is a synergistic effect between MS-related and aging-related brain atrophy is still unknown.
Objectives: To estimate the aging effect on LVV enlargement in MS patients.
Methods: We collected information from 2,104 MS patients aged from 20 to 79 years old, over a period of 10 years (mean time of follow-up 4.4 years), and of 350 HI for cross-sectional comparison purposes. We used Neurological Software Tool for REliable Atrophy Measurement (NeuroSTREAM) to measure LVV on 8,858 brain scans images (min 1, max 24, and median of 3 per subject). LVV changes were determined between all-time points and subjects were divided in 6 decade age groups as follows: 20-29, 30-39, 40-49, 50-59, 60-69 and 70-79 years old. Percent LVV change (PLVVC) differences between age groups were calculated using Student's t-test, and analysis of covariance (ANCOVA), adjusted for age at first MRI, gender, field strength, time of follow up in years, duration of disease from first clinical event to first MRI and LVV at first MRI as covariates.
Results: At first MRI, MS patients had significantly increased LVV in every age decade group compared to HI (p< 0.05). In MS patients, the cumulative PLLVC was 3.6% in age groups 20-59 (n=1,845) and 6.9% in age groups 60-79 (n=259) (p< 0.0001). In ANCOVA analysis, the cumulative PLVVC was 3.7% in age group 20-29, 3.6% in age group 30-39, 3.2% in age group 40-49, 4.0% in age group 50-59, 6.7% in age group 60-69 and 8.2% in age group 70-79 (p=0.004).
Conclusions: Our results suggest the aging effect on LVV enlargement in MS patients.
Disclosure: Study was supported in part by Novartis Pharmaceuticals AG, Switzerland.
Financial Relationships/Potential Conflicts of Interest:
Emanuele Ghione, Niels Bergsland, Jesper Hagemeier, Dejan Jakimovski, Ivo Paunkoski, Deepa P. Ramasamy, Ellen Carl have nothing to disclose.
Michael G. Dwyer has received consultant fees from Claret Medical and research grant support from Novartis.
David Hojnacki has received speaker honoraria and consultant fees from Biogen Idec, Teva Pharmaceutical Industries Ltd., EMD Serono, Pfizer Inc, and Novartis.
Channa Kolb has received speaker honoraria and consultant fees from EMD Serono, Teva Pharmaceuticals, Acorda, Novartis, Genzyme and Biogen-Idec.
Bianca Weinstock- Guttman received honoraria as a speaker and as a consultant for Biogen Idec, Teva Pharmaceuticals, EMD Serono, Genzyme&Sanofi, Novartis and Acorda. Dr Weinstock-Guttman received research funds from Biogen Idec, Teva Pharmaceuticals, EMD Serono, Genzyme&Sanofi, Novartis, Acorda.
Robert Zivadinov received personal compensation from EMD Serono, Genzyme-Sanofi, Claret Medical, Celgene and Novartis for speaking and consultant fees. He received financial support for research activities from Teva Pharmaceuticals, Biogen, Genzyme-Sanofi, Novartis, Claret Medical, Intekrin-Coherus and IMS Health.
Abstract: P1017
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - 19 Neurodegeneration
Background: Brain volume loss is part of lifetime brain changes and it starts to accelerate at the age of 60 in healthy individuals (HI). Lateral ventricular volume (LVV) enlargement is accelerated in multiple sclerosis (MS) patients from the disease onset. Whether there is a synergistic effect between MS-related and aging-related brain atrophy is still unknown.
Objectives: To estimate the aging effect on LVV enlargement in MS patients.
Methods: We collected information from 2,104 MS patients aged from 20 to 79 years old, over a period of 10 years (mean time of follow-up 4.4 years), and of 350 HI for cross-sectional comparison purposes. We used Neurological Software Tool for REliable Atrophy Measurement (NeuroSTREAM) to measure LVV on 8,858 brain scans images (min 1, max 24, and median of 3 per subject). LVV changes were determined between all-time points and subjects were divided in 6 decade age groups as follows: 20-29, 30-39, 40-49, 50-59, 60-69 and 70-79 years old. Percent LVV change (PLVVC) differences between age groups were calculated using Student's t-test, and analysis of covariance (ANCOVA), adjusted for age at first MRI, gender, field strength, time of follow up in years, duration of disease from first clinical event to first MRI and LVV at first MRI as covariates.
Results: At first MRI, MS patients had significantly increased LVV in every age decade group compared to HI (p< 0.05). In MS patients, the cumulative PLLVC was 3.6% in age groups 20-59 (n=1,845) and 6.9% in age groups 60-79 (n=259) (p< 0.0001). In ANCOVA analysis, the cumulative PLVVC was 3.7% in age group 20-29, 3.6% in age group 30-39, 3.2% in age group 40-49, 4.0% in age group 50-59, 6.7% in age group 60-69 and 8.2% in age group 70-79 (p=0.004).
Conclusions: Our results suggest the aging effect on LVV enlargement in MS patients.
Disclosure: Study was supported in part by Novartis Pharmaceuticals AG, Switzerland.
Financial Relationships/Potential Conflicts of Interest:
Emanuele Ghione, Niels Bergsland, Jesper Hagemeier, Dejan Jakimovski, Ivo Paunkoski, Deepa P. Ramasamy, Ellen Carl have nothing to disclose.
Michael G. Dwyer has received consultant fees from Claret Medical and research grant support from Novartis.
David Hojnacki has received speaker honoraria and consultant fees from Biogen Idec, Teva Pharmaceutical Industries Ltd., EMD Serono, Pfizer Inc, and Novartis.
Channa Kolb has received speaker honoraria and consultant fees from EMD Serono, Teva Pharmaceuticals, Acorda, Novartis, Genzyme and Biogen-Idec.
Bianca Weinstock- Guttman received honoraria as a speaker and as a consultant for Biogen Idec, Teva Pharmaceuticals, EMD Serono, Genzyme&Sanofi, Novartis and Acorda. Dr Weinstock-Guttman received research funds from Biogen Idec, Teva Pharmaceuticals, EMD Serono, Genzyme&Sanofi, Novartis, Acorda.
Robert Zivadinov received personal compensation from EMD Serono, Genzyme-Sanofi, Claret Medical, Celgene and Novartis for speaking and consultant fees. He received financial support for research activities from Teva Pharmaceuticals, Biogen, Genzyme-Sanofi, Novartis, Claret Medical, Intekrin-Coherus and IMS Health.